Stomach cancer is also known as gastric cancer. It forms in the cells lining the stomach.
Cancer can also form in the
gastroesophageal junction (GEJ).
The GEJ is the place where the esophagus connects to the stomach.
Most cases of stomach and GEJ cancer in the United States are not caught until they are in the advanced stages.
This means the cancer is either:
It has spread from where it started to nearby tissues or lymph nodes and is unable to be removed with surgery
-or-
It has spread from where it started to other places in the body
*The Surveillance, Epidemiology, and End Results Program of the National Cancer Institute does not have a separate classification for GEJ cancer apart from esophageal cancer; therefore, true GEJ cancer projections are unknown. This makes it difficult to project an estimated number of new cases of GEJ cancer.
One of the things that can differentiate your case of advanced stomach/GEJ cancer is the presence or absence of certain biomarkers.
A biomarker is a molecule that is found in the body. In some cases of cancer, it can be a protein found on the surface of a tumor.
Biomarker testing is used to gather more information about the specific type of cancer. These results help doctors understand the different features of the cancer.
If your cancer tests positive for a specific biomarker, this information can help you and your doctor choose a treatment that may be more appropriate for you.
Targeted therapy is a type of treatment that uses medicines to target specific molecules on cancer cells. Targeted therapies work in different ways to treat cancer. Targeted therapies, while specific, can also affect other tissues in the body.
It is one of the most common biomarkers in stomach and GEJ cancers. Claudin 18.2 is typically found in the stomach lining. When cancer develops, claudin 18.2 may become more exposed at the surface of the cancer cell.